131 related articles for article (PubMed ID: 32041505)
1. Angiotensin II receptor agonist antibodies are associated with microvascular damage in lupus nephritis.
Mejia-Vilet JM; López-Hernández YJ; Santander-Vélez JI; Trujeque-Matos M; Cruz C; Carranza de la Torre CA; Espinosa-Cruz V; Espinosa-González R; Uribe-Uribe NO; Morales-Buenrostro LE
Lupus; 2020 Apr; 29(4):371-378. PubMed ID: 32041505
[TBL] [Abstract][Full Text] [Related]
2. Do circulating antibodies against C1q reflect the activity of lupus nephritis?
Smykał-Jankowiak K; Niemir ZI; Polcyn-Adamczak M
Pol Arch Med Wewn; 2011 Sep; 121(9):287-95. PubMed ID: 21860370
[TBL] [Abstract][Full Text] [Related]
3. [Significance of serum anti-Clq Ab in evaluation of lupus nephritis activity and its curative effects of pharmacotherapy on lupus nephritis].
Cai XY; Yang XY; Chen XH; Liang LQ; Guan MM; Qin SG; Fu JZ
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1436-9. PubMed ID: 15500738
[TBL] [Abstract][Full Text] [Related]
4. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
5. Clinical and functional consequences of anti-properdin autoantibodies in patients with lupus nephritis.
Radanova M; Mihaylova G; Ivanova D; Daugan M; Lazarov V; Roumenina L; Vasilev V
Clin Exp Immunol; 2020 Aug; 201(2):135-144. PubMed ID: 32306375
[TBL] [Abstract][Full Text] [Related]
6. Immunological aspects of biopsy-proven lupus nephritis in Bahraini patients with systemic lupus erythematosus.
Farid EM; Hassan AB; Abalkhail AA; El-Agroudy AE; Arrayed SA; Al-Ghareeb SM
Saudi J Kidney Dis Transpl; 2013 Nov; 24(6):1271-9. PubMed ID: 24231503
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiotensin II type 1 receptor autoantibodies (AT
İlgen U; Yayla ME; Düzgün N
Rheumatol Int; 2017 Apr; 37(4):593-598. PubMed ID: 28004166
[TBL] [Abstract][Full Text] [Related]
8. Activation of the alternative complement pathway predicts renal outcome in patients with lupus nephritis.
Kim H; Kim T; Kim M; Lee HY; Kim Y; Kang MS; Kim J
Lupus; 2020 Jul; 29(8):862-871. PubMed ID: 32408850
[TBL] [Abstract][Full Text] [Related]
9. Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis.
Hung WT; Chen YM; Lan JL; Chen HH; Chen YH; Chen DY; Hsieh CW; Wen MC
Lupus; 2011 Nov; 20(13):1404-10. PubMed ID: 21946514
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis.
Sjöwall C; Olin AI; Skogh T; Wetterö J; Mörgelin M; Nived O; Sturfelt G; Bengtsson AA
Autoimmunity; 2013 May; 46(3):205-14. PubMed ID: 23331132
[TBL] [Abstract][Full Text] [Related]
11. Anti-dsDNA antibodies and resident renal cells - Their putative roles in pathogenesis of renal lesions in lupus nephritis.
Yung S; Chan TM
Clin Immunol; 2017 Dec; 185():40-50. PubMed ID: 27612436
[TBL] [Abstract][Full Text] [Related]
12. Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus.
Metwally IM; Eesa NN; Yacoub MH; Elsman RM
Adv Rheumatol; 2019 Mar; 59(1):10. PubMed ID: 30832710
[TBL] [Abstract][Full Text] [Related]
13. Peripheral arterial disease in patients with systemic lupus erythematosus: a prospective controlled study.
Hassan AA; Habib HM; Eissa AA
Int J Rheum Dis; 2013 Jun; 16(3):319-24. PubMed ID: 23981754
[TBL] [Abstract][Full Text] [Related]
14. [Laboratory and morphologic parameters in patients with lupus nephritis].
Rasković S; Bogić M; Perić-Popadić A; Stefanović L; Arandjelović S; Jovicić Z; Bolpacić J; Tomić-Spirić V
Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():38-41. PubMed ID: 12583312
[TBL] [Abstract][Full Text] [Related]
15. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
Dall'Era M; Stone D; Levesque V; Cisternas M; Wofsy D
Arthritis Care Res (Hoboken); 2011 Mar; 63(3):351-7. PubMed ID: 21080348
[TBL] [Abstract][Full Text] [Related]
16. [The role of anti-nucleosome antibodies in systemic lupus erythematosus. Results of a study of patients with systemic lupus erythematosus and other connective tissue diseases].
Quattrocchi P; Barrile A; Bonanno D; Giannetto L; Patafi M; Tigano V; Ferlazzo B
Reumatismo; 2005; 57(2):109-13. PubMed ID: 15983634
[TBL] [Abstract][Full Text] [Related]
17. [Expression and diagnostic value of plasma miR-145 and miR-183 in children with lupus nephritis].
Lin LJ; Mai LJ; Chen G; Zhao EN; Xue M; Su XD
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Jun; 22(6):632-637. PubMed ID: 32571464
[TBL] [Abstract][Full Text] [Related]
18. Reactivity in ELISA with DNA-loaded nucleosomes in patients with proliferative lupus nephritis.
Dieker J; Schlumberger W; McHugh N; Hamann P; van der Vlag J; Berden JH
Mol Immunol; 2015 Nov; 68(1):20-4. PubMed ID: 26597199
[TBL] [Abstract][Full Text] [Related]
19. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance.
Sinico RA; Radice A; Ikehata M; Giammarresi G; Corace C; Arrigo G; Bollini B; Li Vecchi M
Ann N Y Acad Sci; 2005 Jun; 1050():193-200. PubMed ID: 16014534
[TBL] [Abstract][Full Text] [Related]
20. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis.
Moroni G; Radice A; Giammarresi G; Quaglini S; Gallelli B; Leoni A; Li Vecchi M; Messa P; Sinico RA
Ann Rheum Dis; 2009 Feb; 68(2):234-7. PubMed ID: 18718989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
